Application of ⁶⁸Ga-FXX489 (NNS309) PET/CT Imaging in Diagnosis of Tumor Diseases.
Yi Tian
30 participants
Sep 11, 2025
INTERVENTIONAL
Conditions
Summary
A new radiotracer, 68Ga-FXX489 (NNS309), has been developed for tracking fibroblast activation protein (FAP) and visualizing the tumor stroma. The purpose of the study is to explore the diagnostic value of 68Ga-FXX489 (NNS309) PET/CT imaging in oncological diseases, to assess its safety, imaging characteristics, and biodistribution after administration.
Eligibility
Inclusion Criteria2
- Patients with a high suspicion of oncological diseases.
- Age: 18-80 years, no gender restriction, able to express themselves independently, and willing to participate in this study with a signed informed consent form.
Exclusion Criteria7
- Failure to sign the informed consent form.
- Severe visual or auditory impairment, cognitive disorders, or patients with claustrophobia who cannot communicate effectively.
- Severe cardiac dysfunction, cardiac function class III-IV.
- Renal failure (serum creatinine level \> 1.2 mg/dl).
- Allergy to alcohol.
- Use of drugs within 1 week prior to the examination that can cause a disulfiram-like reaction with alcohol, such as penicillins, cephalosporins, or cefotetan.
- Known pregnancy.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
The dose will be 3 to 8 millicurie (mCi) +/- 10% given intravenously at a single time prior to imaging.
Participants will be scanned for approximately 30 to 45 minutes.
The dose will be 3 to 8 millicurie (mCi) +/- 10% given intravenously at a single time prior to imaging.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07144085